A newly developed bioelectronic comb restored all lost hair in balding mice within a month, outperforming standard topical treatments, according to a study published in the journal Nature Communications. Researchers from China’s Beihang University and City University of Hong Kong designed the handheld tool to stimulate tissue and push therapeutic compounds deep beneath the skin surface during routine combing, ZME Science and DongA Science reported.
The experimental instrument, dubbed Detangle in a nod to the animated film “Tangled,” looks like an ordinary hair comb. However, it incorporates electronic teeth embedded with electrodes of varying heights alongside compartments containing therapeutic substances, according to reports.
How the bioelectronic device works
The device tackles hair loss by combining electrical stimulation with genetic therapy. Electrodes in the comb generate an electric field measured at approximately 260.37 volts per meter, DongA Science reported. The authors noted that this field increases cell membrane permeability, penetrating about nine times deeper than standard external applications. This allows medicinal agents to cross biological barriers and reach hair follicle cells roughly 660 micrometers under the surface.
As the device glides through hair, it releases two simultaneous treatments targeting biological drivers of pattern baldness, formally known as androgenetic alopecia. One component is a DNA plasmid carrying instructions for vascular endothelial growth factor A, or VEGF-A, a protein that promotes the creation of new blood vessels around follicles to boost blood flow, according to ZME Science. The second treatment uses small interfering RNA, known as siRNA, designed to suppress steroid 5-alpha-reductase 2, an enzyme responsible for producing dihydrotestosterone, or DHT. DHT is the hormone primarily responsible for shrinking hair follicles and causing hair to thin.
Testing against standard medications
In animal trials, researchers brushed mice engineered with androgenetic alopecia once every three days for roughly four weeks, according to the published findings. Over that period, the previously bare areas experienced near-complete regrowth, achieving up to 100 percent hair restoration that rendered the treated patches virtually indistinguishable from surrounding fur, DongA Science reported.
By comparison, a control group of mice treated with a daily dose of 0.2 milliliters of minoxidil—the active ingredient in Rogaine—achieved about 70 percent hair recovery over the same period, according to the New York Post and ZME Science. Finasteride, another widely used medication, also failed to match the comb’s results in the trial.
Androgenetic alopecia affects an estimated 50 million men and 30 million women in the United States and more than 1.5 billion people worldwide, news outlets noted. While oral medications can lead to unwanted systemic side effects and topical creams often struggle to penetrate human skin barriers, the study authors stated that the comb provides an alternative approach. Beyond baldness, the researchers told outlets that the delivery method could eventually serve as a platform for administering genetic therapies into deeper skin layers for other dermatological disorders.
Despite the strong outcomes in preclinical testing, the comb has not yet undergone clinical trials in humans. Human skin properties, follicle physiology, and hormonal reactions differ substantially from those of mice, meaning further research is required to evaluate safety, human efficacy, and proper dosing regimens.
